Qyuns Therapeutics has granted Caldera Therapeutics worldwide rights to a preclinical TL1A×IL-17 bispecific antibody (BsAb), receiving a USD 30 million non-refundable upfront payment and eligibility for up to USD 750 million in clinical, regulatory and commercial milestones, plus tiered royalties on net sales.
The deal gives Caldera full global control of research, development, manufacturing and commercialisation while allowing Qyuns to monetise an early-stage immunology asset without carrying the full development burden.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation